Clinical Trial Update: Safety of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy [Phase 1]

View source ↗

Summary

A Phase 1 safety update on epicutaneous immunotherapy for peanut allergy, reporting safety data from DBV Technologies' approach.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peanut Allergy

Drugs mentioned

• Viaskin Peanut (peanut epicutaneous immunotherapy patch)

Snippet

Sponsor: DBV Technologies | Conditions: Peanut Allergy | Phase 1 | Status: COMPLETED